Cargando…

Correction to: Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Correction Notices
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732224/ https://www.ncbi.nlm.nih.gov/pubmed/35932280 http://dx.doi.org/10.1093/oncolo/oyac166

Ejemplares similares

Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab
por: Pasello, Giulia, et al.
Publicado: (2022)

Correction Notice: A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure
Publicado: (2021)

Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea
por: Lim, Sun Min, et al.
Publicado: (2020)

Correction to: Management of Lung Cancer in the Patient with Interstitial Lung Disease
Publicado: (2023)

Correction Notice – Isavuconazole in Hematological Patients: Results of a Real-Life Multicentre Observational Seifem Study
Publicado: (2023)

Correction: Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis
por: Schad, Friedemann, et al.
Publicado: (2022)

Correction: Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
Publicado: (2020)

Correction to: Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real‑world clinical practice: a multicentre retrospective clinical study
por: Hanai, Nobuhiro, et al.
Publicado: (2021)

Correction: Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States
por: Hess, Lisa M., et al.
Publicado: (2023)

Real‐world safety of nivolumab in patients with non‐small‐cell lung cancer in Japan: Postmarketing surveillance
por: Yamamoto, Nobuyuki, et al.
Publicado: (2021)

Correction: Real-world clinical predictors of manic/hypomanic episodes among outpatients with bipolar disorder
Publicado: (2022)

Correction: Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA
por: Li, Yulin, et al.
Publicado: (2019)

Correction to: Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib
por: Tamura, Kazuo, et al.
Publicado: (2019)

CORRECTION
Publicado: (2018)

Correction Notice
Publicado: (2017)

Correction Notice
Publicado: (2017)

Correction Notice
Publicado: (2019)

Correction Notice
Publicado: (2022)

Correction notice
Publicado: (2022)

Correction notice
Publicado: (2022)

Correction Notice: Coronavirus Disease 2019 in Recipient of Allogeneic Hematopoietic Stem Cell Transplantation: Life-threatening Features Within the Early Post-engraftment Phase
Publicado: (2020)

Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma
por: Samlowski, Wolfram, et al.
Publicado: (2022)

Correction to: Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience
por: Tsuboi, Shinya, et al.
Publicado: (2023)

Correction to: Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel
Publicado: (2022)

Real‐world experience of nivolumab in the treatment of poor performance status patients with advanced non‐small cell lung cancer
por: Abbas, M. Nazim, et al.
Publicado: (2021)

Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
por: Alonso-García, Miriam, et al.
Publicado: (2022)

Correction: Methylation Markers of Early-Stage Non-Small Cell Lung Cancer
por: Lokk, Kaie, et al.
Publicado: (2017)

Correction to: Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis
por: Jiang, Huihui, et al.
Publicado: (2021)

Correction to: Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018
por: Liu, Yifei, et al.
Publicado: (2022)

Correction Notice: The EHA Research Roadmap: Anemias
Publicado: (2021)

Correction to: Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage Melanoma
por: Jang, Sekwon, et al.
Publicado: (2020)

Correction notice to: Early results of total hip arthroplasty using dual-mobility cup in patients with osteonecrosis of the femoral head: SICOT-J 2018, 4, 4, https://doi.org/10.1051/sicotj/2018001
por: Assi, Chahine, et al.
Publicado: (2018)

Discontinuation of Routine Distribution of Printed Copies of MMWR Weekly
Publicado: (2014)

Correction to: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1
por: Nishio, Makoto, et al.
Publicado: (2023)

Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial
por: Tamiya, Motohiro, et al.
Publicado: (2018)

Correction to: Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma
Publicado: (2022)

Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%
por: Pons-Tostivint, E., et al.
Publicado: (2023)

Correction: Real-world effectiveness of osteoporosis treatments in Germany
por: O’Kelly, James, et al.
Publicado: (2022)

Nivolumab in Non-Small Cell Lung Cancer: Real World Long-Term Survival Results and Blood-Based Efficacy Biomarkers
por: Daher, Sameh, et al.
Publicado: (2021)

Multi-Center Real-World Outcomes of Nivolumab Plus Ipilimumab and Chemotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer
por: Shalata, Walid, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_58lf37kqere5r0lp4br64s1ij1